Metastatic Cancer Prognosis
In most metastatic cancer prognosis, survival rate for the patient is less as compare to the prognosis in the initial stages of metastatic cancer. This condition depends on several factors such as the general health of the patient, type of the cancer, spread of the cancer cells, size of the tumor, and age of the patient. Metastatic cancer survival rate and prognosis from the time of diagnosis varies for each patient. In many cases, cancer metastases in the bone and creates a chorine condition that requires a range of specific treatments to find the root of cancer and treat it accordingly.
The average survival duration from detection of bone metastases from breast or prostate cancer is measured in four to six years. In contrast to this, the average survival duration from the detection of metastatic lung cancer is usually measured in months. The prognosis of bone metastases into breast cancer is quite better than the intuitive sites after a recurrence. Evidence revealed that the average survival time in the patient with recurrence in skeleton was around 24 months while for the first relapse in liver it was only 3 months.
Prognosis for breast cancer:
Many treatment options have evolved to treat breast cancer and help the patient to survive for longer time. However, even after taking the treatments the cancer may spread into other body structures or organs. Many times cancer recurs even after the removing the entire tumor and detecting the nearby lymph nodes free of cancer cells.
The metastatic cancer prognosis is based on the several factors, but the spread and development of cancer cells is the major factor. The more the cancer is metastasized, the poorer will be the prognosis. Other factors that contribute to the risk of recurrence and possibility of successful treatment involve:
All these factors decide your metastatic breast cancer prognosis.
Prognosis for Brain Cancer:
Prognosis of metastatic brain cancer varies with the location, type, overall health and age of the patient. In general, very rare treatment plans results in complete cure. Reports of five year survival rate (it is considered as the long term survival rate in cancer) vary from 10 percent to 35 percent, no matter which treatment option is selected to treat the patient. Recovery from brain cancer is possible in some cases but complete cure is very rare. Without treatment brain cancers becomes aggressive and results into death in very short duration, while opting for a suitable treatment plan can elevate the life style of the patient for some time. Doctors need to discuss the prognosis with the patient.
Prognosis of Colon Cancer:
Colon cancer can be treated effectively if diagnosed in early stages and the patient can survive for more than five years after the diagnosis. If the colon cancer does not recur (come back) in five years, it is considered to be cured. Metastatic cancer prognosis for colon cancer is very less, but there are exceptions.
Prognosis for Lung Cancer:
A complete cure is unlike in most cases. Chances of the patient with metastatic lung cancer to survive for more than five years are very rare. However the prognosis depends on the type of the primary cancer. Rarely, surgery is a helpful option to cure certain types of cancer which includes kidney cancer, sarcoma, melanoma, colon cancer or bladder cancer that has spread slightly in to the lungs. Some type of cancers that has metastasized in lungs (particularly testicular cancer or lymphoma) can be cured when treated with chemotherapy.
Prognosis of Prostate Cancer:
Prognosis of this type cancer varies greatly, as it mostly depends on the abnormality of the tumor and whether the cancer cells have spread beyond the prostate gland during diagnosis. If the cancer has not spread at large extent, the patient may survive for more than five years. For patient who cannot be cured completely, hormonal treatment is a helpful option to increase life expectancy for metastatic cancer. Metastatic cancer prognosis for all types of cancers generally, depends on the location, size, grade and the extent of cancer cells spread.